Thursday, February 28, 2019

Top 10 Vehicles to Buy Used, Not New

Buying a one-year-old used car can save consumers 23% compared to buying the new model of the same car. Depending on the model, savings could be more than double according to auto research firm iSeeCars.com.

The firm has analyzed more than 7 million new and used car sales from August 2018 to January 2019 and compared the prices of new vehicles to prices of their one-year-old versions to identify those with the greatest price differences.

iSeeCars CEO Phong Ly noted, “While purchasing a new car offers peace of mind, waiting a year and purchasing the same vehicle lightly used can amount to significant savings. Consumers who buy a lightly used car can still take advantage of the remaining manufacturer warranties and can have the car inspected by an independent mechanic prior to purchasing to ease any uncertainties about the vehicle's condition and driving history.”

Here’s the iSeeCars list of the 10 vehicles car buyers may want to purchase used instead of new, including the percentage difference and the dollar difference for a used car over a new one.

Rank/Model % Difference $ Difference
1. Ford Expedition -38.50% $24,690
2. Kia Sedona -37.80% $12,918
3. Chevrolet Impala -36.40% $11,837
4. Infiniti QX80 -34.90% $26,188
5. Ford Fusion Hybrid -34.30% $9,301
6. Infiniti Q50 -33.10% $14,938
7. Nissan Altima -32.60% $7,984
8. Hyundai Santa Fe Sport -31.40% $9,368
9. Kia Optima -31.30% $7,574
10. Hyundai Accent -31.00% $5,136

 

Of the 10 vehicles listed, six are passenger cars, three are sport utility vehicles and one is a minivan. The Ford Expedition is the most expensive SUV in its class, and a used version must be priced at a substantial discount in order to sell.

As for the passenger cars, they are losing their popularity both as news and used vehicles. The used vehicles on this list are not among the top-rated vehicles in their class, accounting for the steep discounts for a one-year-old model according to iSeeCars.

Among SUVs, the average percentage difference in price for a used vehicle is 17.7% compared to a new vehicle. In addition to the three SUVs that made the top-10 list, at least seven more beat that average, including the Kia Sportage, Nissan Rogue, GMC Yukon XL and Mitsubishi Outlander. Again, most of these vehicles dwell in the lower part of the rankings in their class and have to be priced low in order to sell.

Three pickups offer a better value for buyers when purchased used rather than new: the Ram 1500, GMC Sierra 1500 and Nissan Titan. The average difference is 20.7% for a used versus new pickup. All are full-sized models and, like the Expedition, require significant discounts to the new price in order to attract buyers.

Luxury cars suffer both from being less attractive to buyers than SUVs and from their high new-vehicle prices. The average discount for a year-old luxury vehicle, car or SUV, is 16.6%.

Small hybrid and all-electric cars have an overall 28.1% discount for a used versus a new model. Partly that’s due to low overall demand for electrified cars. A one-year-old Nissan Leaf, for example, can be purchased for 40% below the cost of a new model. Among the hybrids, lower fuel economy also weighs on the resale price of a year-old version.

Visit the iSeeCars website for the full report and methodology.

24/7 Wall St.
Goldman Sachs Raises Price Targets on 4 Red-Hot Stocks

Thursday, February 21, 2019

Community Health Systems (CYH) Posts Quarterly Earnings Results, Beats Expectations By $0.17 EPS

Community Health Systems (NYSE:CYH) issued its quarterly earnings results on Wednesday. The company reported ($0.42) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.17, Bloomberg Earnings reports. The firm had revenue of $3.45 billion during the quarter, compared to analysts’ expectations of $3.38 billion. The firm’s revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.28) EPS. Community Health Systems updated its FY 2019 guidance to $-1.6–1.25 EPS.

CYH stock traded up $0.09 during midday trading on Wednesday, reaching $4.07. The company had a trading volume of 1,337,700 shares, compared to its average volume of 1,668,517. Community Health Systems has a 1 year low of $2.48 and a 1 year high of $6.28. The company has a market cap of $459.32 million, a price-to-earnings ratio of -3.39 and a beta of 2.51.

Get Community Health Systems alerts:

Several brokerages recently commented on CYH. Cantor Fitzgerald reduced their price target on shares of Community Health Systems from $6.00 to $4.00 and set a “neutral” rating for the company in a research report on Wednesday, October 31st. UBS Group began coverage on shares of Community Health Systems in a research report on Thursday, November 15th. They issued a “sell” rating and a $2.00 price target for the company. Zacks Investment Research downgraded shares of Community Health Systems from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Finally, ValuEngine downgraded shares of Community Health Systems from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. Five investment analysts have rated the stock with a sell rating and seven have assigned a hold rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $3.50.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4166990/community-health-systems-cyh-posts-quarterly-earnings-results-beats-expectations-by-0-17-eps.html.

Community Health Systems Company Profile

Community Health Systems, Inc, together with its subsidiaries, owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services.

Read More: Municipal Bonds

Earnings History for Community Health Systems (NYSE:CYH)

Zacks: Brokerages Anticipate Teekay Lng Partners, L.P. (TGP) to Post $0.34 Earnings Per Share

Wall Street analysts predict that Teekay Lng Partners, L.P. (NYSE:TGP) will report earnings per share of $0.34 for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Teekay Lng Partners’ earnings, with estimates ranging from $0.28 to $0.42. Teekay Lng Partners posted earnings per share of $0.35 in the same quarter last year, which indicates a negative year over year growth rate of 2.9%. The company is scheduled to issue its next earnings report before the market opens on Thursday, February 21st.

According to Zacks, analysts expect that Teekay Lng Partners will report full-year earnings of $0.84 per share for the current fiscal year, with EPS estimates ranging from $0.76 to $0.88. For the next fiscal year, analysts forecast that the business will post earnings of $1.83 per share, with EPS estimates ranging from $1.41 to $2.15. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Teekay Lng Partners.

Get Teekay Lng Partners alerts:

TGP has been the subject of several research reports. ValuEngine upgraded shares of Teekay Lng Partners from a “sell” rating to a “hold” rating in a research report on Saturday, October 27th. Jefferies Financial Group reiterated a “neutral” rating on shares of Teekay Lng Partners in a research report on Tuesday, November 20th. Wells Fargo & Co cut their target price on shares of Teekay Lng Partners from $22.00 to $15.00 and set an “outperform” rating for the company in a research report on Wednesday, November 21st. Stifel Nicolaus upgraded shares of Teekay Lng Partners from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Wednesday, November 28th. Finally, TheStreet upgraded shares of Teekay Lng Partners from a “d+” rating to a “c” rating in a research report on Monday, November 26th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $17.00.

Large investors have recently made changes to their positions in the stock. Banco de Sabadell S.A grew its position in Teekay Lng Partners by 188.1% in the third quarter. Banco de Sabadell S.A now owns 6,914 shares of the shipping company’s stock worth $112,000 after acquiring an additional 4,514 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in Teekay Lng Partners in the fourth quarter worth $116,000. Virtu Financial LLC purchased a new position in Teekay Lng Partners in the fourth quarter worth $121,000. LPL Financial LLC purchased a new stake in Teekay Lng Partners during the third quarter valued at about $218,000. Finally, Valmark Advisers Inc. boosted its position in Teekay Lng Partners by 12.5% during the fourth quarter. Valmark Advisers Inc. now owns 15,199 shares of the shipping company’s stock valued at $167,000 after buying an additional 1,690 shares during the period. Institutional investors own 30.41% of the company’s stock.

Shares of Teekay Lng Partners stock traded up $0.26 during trading on Wednesday, hitting $13.45. The stock had a trading volume of 682,100 shares, compared to its average volume of 333,659. The stock has a market cap of $1.05 billion, a P/E ratio of 13.47 and a beta of 1.52. Teekay Lng Partners has a 12 month low of $10.74 and a 12 month high of $19.45. The company has a debt-to-equity ratio of 1.83, a quick ratio of 0.72 and a current ratio of 0.72.

The business also recently announced a quarterly dividend, which was paid on Friday, February 8th. Investors of record on Friday, February 1st were given a $0.14 dividend. The ex-dividend date was Thursday, January 31st. This represents a $0.56 annualized dividend and a yield of 4.16%. Teekay Lng Partners’s dividend payout ratio (DPR) is presently 56.00%.

About Teekay Lng Partners

Teekay LNG Partners L.P. provides marine transportation services for liquefied natural gas (LNG), liquefied petroleum gas (LPG), and crude oil worldwide. The company operates through two segments, Liquefied Gas and Conventional Tanker. It transports liquid petroleum gases, including propane, butane, and ethane; petrochemical gases, such as ethylene, propylene, and butadiene; and ammonia.

Read More: Float

Get a free copy of the Zacks research report on Teekay Lng Partners (TGP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Tuesday, February 19, 2019

Zumiez Inc. Stock Rises 7.6% Following Same-Store Sales Report (NASDAQ:ZUMZ)

Zumiez’s (NASDAQ:ZUMZ) same-store sales increased by 4.9% during the month of January. Zumiez’s stock rose by 7.6% in the first full-day of trading following the news.

A number of research analysts have weighed in on the stock. BidaskClub lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Thursday. Zacks Investment Research lowered shares of Zumiez from a “buy” rating to a “hold” rating in a research note on Saturday, January 26th. DA Davidson reaffirmed a “neutral” rating and issued a $20.00 price objective on shares of Zumiez in a research note on Friday, December 7th. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, November 20th. Finally, Pivotal Research set a $30.00 price objective on shares of Zumiez and gave the company a “buy” rating in a research note on Thursday, November 8th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $25.43.

Get Zumiez alerts:

ZUMZ opened at $24.22 on Friday. Zumiez has a fifty-two week low of $17.57 and a fifty-two week high of $32.70. The stock has a market cap of $599.96 million, a P/E ratio of 22.02, a PEG ratio of 1.03 and a beta of 1.29.

Zumiez (NASDAQ:ZUMZ) last released its quarterly earnings results on Thursday, December 6th. The apparel and footwear maker reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.06. Zumiez had a net margin of 3.62% and a return on equity of 10.06%. The company had revenue of $248.80 million for the quarter, compared to analyst estimates of $248.70 million. During the same period last year, the firm earned $0.48 earnings per share. The firm’s revenue was up 1.2% on a year-over-year basis. On average, research analysts predict that Zumiez will post 1.73 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Trust Advisors LP bought a new position in shares of Zumiez during the third quarter valued at about $756,000. GSA Capital Partners LLP bought a new stake in Zumiez in the third quarter worth about $213,000. Credit Suisse AG raised its position in Zumiez by 125.0% in the third quarter. Credit Suisse AG now owns 22,811 shares of the apparel and footwear maker’s stock worth $600,000 after acquiring an additional 12,673 shares during the period. Vanguard Group Inc raised its position in Zumiez by 9.9% in the third quarter. Vanguard Group Inc now owns 2,199,058 shares of the apparel and footwear maker’s stock worth $57,945,000 after acquiring an additional 197,221 shares during the period. Finally, SG Americas Securities LLC raised its position in Zumiez by 225.4% in the third quarter. SG Americas Securities LLC now owns 54,403 shares of the apparel and footwear maker’s stock worth $1,434,000 after acquiring an additional 37,684 shares during the period. 82.23% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was published by Ticker Report and is owned by of Ticker Report. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/4155622/zumiez-inc-stock-rises-7-6-following-same-store-sales-report-nasdaqzumz.html.

About Zumiez

Zumiez Inc, together with its subsidiaries, operates as a specialty retailer of apparel, footwear, accessories, and hardgoods for young men and women. Its hardgoods include skateboards, snowboards, bindings, components, and other equipment. As of September 1, 2018, the company operated 703 stores, including 610 stores in the United States, 50 stores in Canada, 36 stores in Europe, and 7 stores in Australia under the names of Zumiez, Blue Tomato, and Fast Times.

See Also: Municipal Bonds

Monday, February 18, 2019

The 3 Most Important Takeaways From Canopy Growth's Quarterly Results

The world's leading medical marijuana company, Canopy Growth (NYSE:CGC), just unveiled its fourth-quarter financials, and the performance reaffirms its status as the top dog in this emerging industry. The results are particularly important because they include the first six weeks of sales from Canada's new recreational marijuana market. Before you buy shares in this top cannabis company, here's what you should know.

1. Still the big kahuna

When top competitor Aurora Cannabis (NYSE:ACB) reported quarterly results earlier this week, it said it nabbed recreational market share of 20% and that recreational sales represented 21.6 million Canadian dollars of its CA$54 million in net sales. Canopy Growth crushed those figures.

Marijuana buds sitting next to a stack of $100 bills.

Image source: Getty Images.

Its CA$83 million in revenue was 54% higher than Aurora Cannabis' haul. In the past, Canopy Growth has estimated its medical market share exceeds 30% and it appears it's executing even better in the recreational market. Using Aurora Cannabis 20% recreational market share figure and its CA$21.6 in recreational sales, we can estimate total recreational sales were somewhere around $108 million. Canopy Growth's recreational sales were CA$57.7 million, so by that back-of-napkin math, it nabbed a whopping 53.4% of the estimated adult-use market last quarter.

2. Product mix is improving

In the same quarter last year, Canopy Growth sold 2,330 kilograms of marijuana. In Q4, it sold 10,102 kilograms -- a 335% increase.

Importantly, a lot of the marijuana it sold was as high-margin products. Specifically, oils and soft gels accounted for 33% revenue in the period, up from 23% last year. In the medical marijuana market, these products represented 42% of revenue. They accounted for 30% of recreational market revenue.

Increasing revenue from oils and soft gels, plus the potential to sell vapes, beverages, and edibles in Canada at some point, should help improve gross margin. After adjustments for non-cultivating subsidiaries and excise taxes it absorbed, gross margin was 40% last quarter. That's low relative to peers, but Canopy Growth believes that as new facilities ramp to scale and value-added products launch, margin will trend up over time. By comparison, Aurora Cannabis' gross margin was 54% last quarter.

Marijuana buds in front of an American flag.

Image source: Getty Images.

3. Its U.S. strategy remains on track

In January, Canopy Growth announced it had obtained a license to process hemp products in New York state. It plans to invest up to $150 million to become an anchor tenant in a hemp-focused industrial park at a location to be determined. In its earnings conference call, the company told investors that it has identified the site for this industrial park and negotiations are ongoing. 

Management isn't tipping its hand on what could be the first hemp-derived products to launch in New York, but they did suggest that health and wellness products for pets and humans are being targeted, and that if everything goes as planned, the first of these products could be available in New York by the end of 2019 or the first quarter of 2020.

As far as plans to expand into other U.S. states, CEO Bruce Linton said on the conference call with investors it will be "sooner than later," but he also added, "It will depend on politics." 

 

Sunday, February 17, 2019

Brokerage calls: Deutsche Bank cuts target price of ONGC

We have collated a list of recommendations from various global brokerage firms for February 15.

ONGC | Brokerage: Deutsche Bank | Rating: Buy | Target: Rs 187

The brokerage cut its target price of ONGC to Rs 187 from Rs 216, retaining the Buy call.

"Maintain Buy rating given inexpensive valuations and sensitivity to oil prices," Deutsche Bank said in a research note.

related news Safari Industries Q3 review: A quarterly blip but long-term story strong First Cut | RBI's clean chit was what the Yes Bank stock was waiting for Brokerage calls: Jefferies slashes target price for Coal India, Hindalco

Deutsche Bank cut its FY19-20 earnings estimate for ONGC by 4 percent.

ONGC | Brokerage: Citi | Rating: Neutral | Target: Rs 172

ONGC's EBITDA beat estimates due to lower than expected operating expenditure, said Citi.

There is room for the government to reduce its stake in the company, according to Citi.

Page Industries | Brokerage: Credit Suisse | Rating: Neutral | Target: Rs 23,300

Credit Suisse said it upgraded the stock to neutral from underperform, and raised the target price to Rs 23,300 from Rs 22,000.

Expect the downgrade cycle to be over, Credit Suisse said.

Ashok Leyland | Brokerage: Nomura | Rating: Neutral | Target: Rs 123

"Margin may be weak on weak operating leverage and high discounts by competition," Nomura said in a research note.

The brokerage expects medium and heavy commercial vehicles industry to peak in FY20, hence has a weak outlook on Ashok Leyland.

Sadbhav Engineering | Brokerage: CLSA | Rating: Buy | Target: Rs 340

CLSA cut the stock's target price to Rs 340 from Rs 390, keeping the Buy call.

"New strategy to churn capital should reach fruition in March end," the brokerage said.

CLSA cut its FY19-21 EPS estimate for the company by 5-6 percent.

(Disclaimer: The above report is compiled from information available on public platforms. Moneycontrol.com advises users to check with certified experts before taking any investment decisions) First Published on Feb 15, 2019 01:03 pm

Saturday, February 16, 2019

Schneider Electric (SU) PT Set at €73.00 by JPMorgan Chase & Co.

Schneider Electric (EPA:SU) received a €73.00 ($84.88) price target from JPMorgan Chase & Co. in a report issued on Thursday. The firm currently has a “buy” rating on the stock.

A number of other equities analysts have also recently issued reports on SU. Berenberg Bank set a €74.00 ($86.05) price objective on shares of Schneider Electric and gave the company a “buy” rating in a research report on Monday, November 19th. Goldman Sachs Group set a €80.00 ($93.02) price objective on shares of Schneider Electric and gave the company a “neutral” rating in a research report on Thursday, October 25th. Kepler Capital Markets set a €60.00 ($69.77) price objective on shares of Schneider Electric and gave the company a “neutral” rating in a research report on Monday, January 14th. Bank of America set a €66.00 ($76.74) price objective on shares of Schneider Electric and gave the company a “neutral” rating in a research report on Tuesday, January 8th. Finally, Societe Generale set a €83.00 ($96.51) price objective on shares of Schneider Electric and gave the company a “buy” rating in a research report on Friday, October 26th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of €71.13 ($82.70).

Get Schneider Electric alerts:

Schneider Electric has a one year low of €64.88 ($75.44) and a one year high of €76.34 ($88.77).

Schneider Electric Company Profile

Schneider Electric S.E. provides energy management and automation solutions worldwide. It operates through four businesses: Low Voltage, Medium Voltage, Industrial Automation, and Secure Power. The Low Voltage business provides low voltage power and building automation products and solutions that address the needs of various end markets from buildings to industries and infrastructure to data centers.

Further Reading: Float

Analyst Recommendations for Schneider Electric (EPA:SU)

Friday, February 15, 2019

Top 5 Value Stocks To Buy For 2019

tags:LXK,GCGMF,FRPH,MBA,AVY,

Shutterstock

Here are some of the most common mistakes parents make, and how you can avoid them.

Big Mistake #1:  Believing That Your Kids Must Have What Other Kids Have

Whether you call it a temptation or a trap, many parents talk themselves into believing that their kids should have what their friends or peers have.  This mistake probably goes back to our childhoods.  If we grew up having less than other kids, or feeling that we did, then we don't want it to happen to our children.  That's a large part of why we work so hard to succeed.

Is this a value we want our children to have?  Do we want them to have that sense of entitlement - "I should have what he has."  "I've got to keep up with the Joneses?"  Of course, we don't.  I am not saying that your kids can't have anything; I'm talking about balance.  The main problem with the syndrome of "keeping up the Joneses" is that there's no cutoff point.  Once you're in that mindset, nothing is ever enough.

Top 5 Value Stocks To Buy For 2019: Lexmark International, Inc.(LXK)

Advisors' Opinion:
  • [By Stephan Byrd]

    Headlines about Lexmark International (NYSE:LXK) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Lexmark International earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media coverage about the technology company an impact score of 42.803224128124 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

  • [By Max Byerly]

    Press coverage about Lexmark International (NYSE:LXK) has been trending somewhat negative on Saturday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Lexmark International earned a coverage optimism score of -0.10 on Accern’s scale. Accern also gave media coverage about the technology company an impact score of 42.9230217304115 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Top 5 Value Stocks To Buy For 2019: Great Canadian Gaming Corporation (GCGMF)

Advisors' Opinion:
  • [By SEEKINGALPHA.COM]

    Clairvest Group previously initiated an investment in a partnership that involved Great Canadian Gaming Corporation (OTCPK:GCGMF) and Brookfield Business Partners LP to operate two casinos in Southern Ontario. With this announcement, we not only get the upside of a 45% ownership of "Ontario Gaming West GLA Limited Partnership," which includes four major operations, but also 2,500 slot machines, 60 table games, racing track and $450 million in gross gaming revenue. Clairvest has a history in the gambling industry and Great Canadian Gaming Corporation is a proven operator with a terrific track record.

Top 5 Value Stocks To Buy For 2019: FRP Holdings, Inc.(FRPH)

Advisors' Opinion:
  • [By Shane Hupp]

    FRP (NASDAQ:FRPH) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Friday.

  • [By Joseph Griffin]

    FRP (NASDAQ:FRPH) was downgraded by equities researchers at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

  • [By Max Byerly]

    FRP Holdings Inc (NASDAQ:FRPH) VP John D. Milton, Jr. sold 3,000 shares of the stock in a transaction that occurred on Thursday, June 14th. The stock was sold at an average price of $59.07, for a total value of $177,210.00. Following the transaction, the vice president now owns 632 shares in the company, valued at approximately $37,332.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Top 5 Value Stocks To Buy For 2019: (MBA)

Advisors' Opinion:
  • [By Max Byerly]

    CIBT Education Group Inc. (TSE:MBA) Director Toby Chu purchased 15,500 shares of CIBT Education Group stock in a transaction that occurred on Friday, August 17th. The shares were bought at an average price of C$0.83 per share, with a total value of C$12,865.00.

Top 5 Value Stocks To Buy For 2019: Avery Dennison Corporation(AVY)

Advisors' Opinion:
  • [By Max Byerly]

    These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:

    Get Avery Dennison alerts: Avery Dennison (AVY) Shares Cross Below 200 DMA (nasdaq.com) Avery Dennison (AVY) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com) Concern in Framingham about environmental contamination (metrowestdailynews.com) Avery Dennison (AVY) Rating Lowered to Hold at Zacks Investment Research (americanbankingnews.com) Avery Dennison (AVY) Upgraded at Zacks Investment Research (americanbankingnews.com)

    Several equities research analysts recently commented on AVY shares. Citigroup dropped their price objective on Avery Dennison from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Thursday, April 5th. Zacks Investment Research raised Avery Dennison from a “hold” rating to a “buy” rating and set a $132.00 price objective on the stock in a research report on Monday, February 5th. UBS started coverage on Avery Dennison in a research report on Thursday, January 18th. They set a “buy” rating and a $135.00 price objective on the stock. Bank of America increased their price objective on Avery Dennison from $128.00 to $133.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. Finally, KeyCorp reaffirmed a “hold” rating on shares of Avery Dennison in a research report on Wednesday, April 25th. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $123.00.

  • [By Ethan Ryder]

    OMERS ADMINISTRATION Corp decreased its holdings in shares of Avery Dennison Corp (NYSE:AVY) by 9.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,500 shares of the industrial products company’s stock after selling 7,500 shares during the period. OMERS ADMINISTRATION Corp owned approximately 0.08% of Avery Dennison worth $7,096,000 as of its most recent SEC filing.

  • [By Lisa Levin] Companies Reporting Before The Bell Thermo Fisher Scientific Inc. (NYSE: TMO) is projected to report quarterly earnings at $2.4 per share on revenue of $5.63 billion. Ford Motor Company (NYSE: F) is expected to report quarterly earnings at $0.41 per share on revenue of $37.16 billion. Twitter, Inc. (NYSE: TWTR) is projected to report quarterly earnings at $0.11 per share on revenue of $605.26 million. Comcast Corporation (NASDAQ: CMCSA) is expected to report quarterly earnings at $0.59 per share on revenue of $22.75 billion. General Dynamics Corporation (NYSE: GD) is estimated to report quarterly earnings at $2.52 per share on revenue of $7.6 billion. The Boeing Company (NYSE: BA) is expected to report quarterly earnings at $2.58 per share on revenue of $22.24 billion. Anthem, Inc. (NYSE: ANTM) is estimated to report quarterly earnings at $4.91 per share on revenue of $22.52 billion. Viacom, Inc. (NASDAQ: VIAB) is projected to report quarterly earnings at $0.79 per share on revenue of $3.04 billion. Northrop Grumman Corporation (NYSE: NOC) is estimated to report quarterly earnings at $3.61 per share on revenue of $6.61 billion. Rockwell Automation Inc. (NYSE: ROK) is expected to report quarterly earnings at $1.81 per share on revenue of $1.66 billion. Wipro Limited (NYSE: WIT) is projected to report quarterly earnings at $0.07 per share on revenue of $2.15 billion. The Goodyear Tire & Rubber Company (NASDAQ: GT) is expected to report quarterly earnings at $0.46 per share on revenue of $3.82 billion. Owens Corning (NYSE: OC) is projected to report quarterly earnings at $0.97 per share on revenue of $1.62 billion. T. Rowe Price Group, Inc. (NASDAQ: TROW) is estimated to report quarterly earnings at $1.71 per share on revenue of $1.29 billion. Dr Pepper Snapple Group, Inc. (NYSE: DPS) is expected to report quarterly earnings at $1.04 per share on revenue of $1.57 billion. Sirius XM Holdings Inc. (NASDAQ: SI
  • [By Ethan Ryder]

    Calamos Advisors LLC raised its position in Avery Dennison Corp (NYSE:AVY) by 11.2% in the second quarter, Holdings Channel reports. The fund owned 40,597 shares of the industrial products company’s stock after buying an additional 4,088 shares during the period. Calamos Advisors LLC’s holdings in Avery Dennison were worth $4,145,000 as of its most recent SEC filing.

Thursday, February 14, 2019

Brokerage calls: Jefferies slashes target price for Coal India, Hindalco

We have collated a list of recommendations from various global brokerage firms for Wednesday, February 13.

NCC | Brokerage: CLSA | Rating: Buy | Target: Rs 140

CLSA raised NCC's target price to Rs 140 from Rs 135, keeping the buy call.

"Affordable housing and highway programme will create years of growth visibility," the brokerage said in a research note.

related news Brokerage calls: CLSA maintains Outperform on Eicher Motors, Motherson Sumi VIP Industries: Subdued Q3 doesn't take away from the long-term story; accumulate Weekly Tactical Pick: Shriram Transport Finance

Coal India | Brokerage: CLSA | Rating: Buy | Target: Rs 275

The brokerage has cut Coal India's target price to Rs 275 from Rs 310, maintaining the buy rating.

The demand outlook looks decent, according to CLSA.

CLSA cut its FY19-21 EPS estimates for Coal India by 3-5 percent due to lower volumes.

Coal India | Brokerage: Jefferies | Rating: Buy | Target: Rs 309

Jefferies has slashed the stock's target price to Rs 309 from Rs 350, retaining the buy call.

"Maintain buy given cheap valuation and strong dividend yield potential," the brokerage said in a research note.

Jefferies cut its FY19/20 EBITDA estimate for the company by 2 percent/0.7 percent, taking into account lower volumes.

Indian Hotels (IHCL) | Brokerage: Morgan Stanley | Rating: Overweight | Target: Rs 174

Morgan Stanley said the pick-up in pricing growth in December 2019 and January 2019 was a key positive in Q3.

The brokerage said it's maintaining the Outperform rating due to IHCL's focus on portfolio growth.

Hindalco Industries | Brokerage: Jefferies | Rating: Buy | Target: Rs 282

Jefferies lowered Hindalco's target price to Rs 282 from Rs 312, keeping the buy rating.

Reduce FY19-20 EBITDA estimates for the company by 2-8 percent, said Jefferies.

Hindalco Industries | Brokerage: CLSA | Rating: Sell | Target: Rs 195

CLSA has cut the stock's target price to Rs 195 from Rs 210, retaining the sell call.

"We cut FY20-21 EPS estimates by 1-9 percent on lower aluminium prices," CLSA said.

Disclaimer: The above report is compiled from information available on public platforms. Moneycontrol.com advises users to check with certified experts before taking any investment decisions. First Published on Feb 13, 2019 11:33 am

Wednesday, February 13, 2019

90% of America's Workers Want This

Few people would go regularly to a restaurant that offered one item, served one way, with no opportunity for customization. Even someone who really enjoyed that dish would probably tire pretty quickly of it, and the vast majority of the public would either never go or visit only once.

That hasn't stopped companies from taking a one-size-fits-all approach to employees. That's been very evident in the open-office trend. Many businesses have implemented that setup without considering what their employees actually want.

In reality, the best way to retain workers and keep office morale might be to offer employees more choice. Most workers -- a full 90% -- said more flexible work arrangements and schedules will increase morale, according to the 2019 Staples Workplace Survey.

Workers cluster around a computer.

Workers place a high level of value on flexibility. Image source: Getty Images.

What do workers want?

Workers want choice, and they're not in favor of offices that take a one-size-fits-all approach. Specifically, 52% said "an open office layout creates distractions," while 40% said their office is "too open."

Employees aren't necessarily asking for a return to closed offices. Instead, they want more choice -- private rooms for calls and meetings, as well as the ability to work from home when possible. In fact, 64% of workers said they work from home at least some of the time, but only 34% of employers have a formal or informal policy regulating that work. 

That's a situation that could lead to worker discontent if a company tries to tighten up its policy. Two-thirds of survey respondents (67%) said they "would consider leaving their job if their work arrangements became less flexible."

Addressing workplace flexibility requires a company to engage in a dialogue with its employees. It also means thinking about the relationship between work and worker in a different way.

"The concept of work-life balance has given way to the simpler concept of 'work life' -- one's life at work," said Staples Brand Group Vice President Chris DeMeo in a press release. "Employees no longer embrace the traditional 9-to-5 and instead seek an environment that accommodates the fact that their needs may change day to day." 

What can your company do?

Offering flexibility is harder than having a single policy that applies in all situations. You need to craft rules that work for the entire workforce without favoring one person or group over another. That requires a thoughtful discussion -- maybe a lot of them -- and a willingness to constantly re-evaluate.

"The smartest employers are acknowledging this reality and offering their workers more autonomy when it comes to where, when, and how they work," DeMeo said. "It may be a leap of faith for offices used to the old ways of doing things, but it's one that could yield dividends in terms of recruitment, retention, and productivity."

There's no single answer here that applies to every company. Instead, employers need to embrace that what seems right for them may not be what's best for their employees. Finding solutions requires a willingness to give employees a voice and to change policies that may have been in place for a very long time.

Monday, February 11, 2019

CBL & Associates Properties, Inc. (CBL) Q3 Earnings Conference Call Transcript

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

Image source: The Motley Fool.

CBL & Associates Properties, Inc. (NYSE:CBL)Q4 2018 Earnings Conference CallFebruary 8, 2019, 11:00 a.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Good day. And welcome to the CBL Properties fourth quarter earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the * key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press * then 1 on your telephone keypad. To withdraw your question, please press * then 2. Please note this event is being recorded. I would now like to turn the conference over to Katie Reinsmidt, CIO. Please go ahead, ma'am.

Katie Reinsmidt -- Chief Investment Officer

Thank you. And good morning. Joining me today are Stephen Lebovitz, CEO and Farzana Khaleel, Executive Vice President and CFO. This conference call contains forward-looking statements within the meaning of the Federal Securities Laws. Such statements are inherently subject to risks and uncertainties. Future events and actual results, financial and otherwise, may differ materially. We direct you to the company's varied filings with the SEC for a detailed discussion of these risks. A reconciliation of supplemental non-GAAP financial measures to the comparable GAAP financial measures was included in yesterday's earnings release and supplemental that will be furnished on Form 8-K and is available in the invest section of the website at cblproperties.com.

This call is being limited to one hour. In order to provide time for everyone to ask questions, we ask that each speaker limit their questions to two and then return to the queue to ask additional questions. If you have questions that were not answered during today's call, please reach out to me following the conclusion of the call. I will now turn it over to Stephen.

Stephen Lebovitz -- Chief Executive Officer

Thank you, Katie. And good morning, everyone. Before I talk about our results for the quarter and the year, I wanna start off with some commentary on our new bank facility which closed last week. This $1.185 billion financing which recast our existing term loans in lines of credit is a huge accomplishment for CBL. It provides us with the runway and flexibility to achieve our redevelopment operational goals over the next several years. Sixteen banks are part of the new facility. And we appreciate their support and vote of confidence. I am also proud of everyone in the CBL organization for all of their hard work and accomplishments in 2018. We have an incredible team of professionals at CBL. And I'm constantly impressed by the dedication and creativity they demonstrate every day. We are pleased to deliver results in line with expectations set forth at the beginning of the year, notwithstanding the challenges that materialized.

This result was accomplished despite bankruptcy filings by two department store chains as well as overall pressure on several national retailers. In addition to the new credit facility, we successfully executed a number of important financial goals in 2018 with more than $340 million in financing activity. This included two non-recourse property-level financings at very favorable rates. We also completed more than $100 million in gross dispositions, supplementing free cash flow and contributing to lower total debt at year-end. And in January, we completed the sale of Cary Towne Center and a deed in lieu on an Acadiana Mall which will reduce overall debt by another $160 million. As I stated, our operational results for the full year were in line with guidance and expectations. Fourth quarter same-center NOI improved from the year-to-date trend with NOI declining 4.4% and full-year same-center NOI declining 6%.

This improvement was due to both effective management of expenses and contributions to the top-line from new leasing and project openings. Adjusted FFO for the fourth quarter was $0.45 per share. And for the full year, it was $1.73 per share. We are never satisfied with negative numbers. And our entire organization is focused on stabilizing NOI and FFO and returning the company to growth. We ended the year with portfolio sales of $377 per square foot compared with $375 per square foot for the prior-year period. Additionally, portfolio occupancy demonstrated improvement with a 110-basis point sequential increase to 93.1%. With 2018 behind us, we are executing on our strategic priorities for 2019. Between the bankruptcy filings of Bon-Ton of Sears, we have more than 40 anchor closures.

As our guidance for this year indicates, the red loss from anchor closures as well as rent reductions and store closures related to bankrupt or struggling shop tenants is having a significant near-term impact to our income stream. At the same time, we now have the opportunity to transform our properties by bringing in newer, more dynamic uses which will help to stabilize income and strengthen our portfolio for the long term. These new users will drive greater sales in traffic and solidify the market-dominant position of our properties for years to come. While in the past, our tenants were limited to primarily national apparel retailers, today, the uses are wide-ranging. In 2018, over 67% of our total new leasing was executed with non-apparel tenants, including dining, entertainment, value, and service.

We are currently under construction, have agreements executed, or in active negotiation on three multi-family projects, 11 entertainment operators, 11 hotels, 38 restaurants, three fitness centers, three medical uses, three sub-storage facilities, two grocers, and a number of other non-retail uses. It's encouraging to report the amount of activity that we have going on across our portfolio. These deals take time to execute. But they will be positive additions to our properties. We are also paying close attention to the capital requirement of backfilling closing stores. I want to highlight that across our portfolio, we have a dozen anchor replacements that are expected to occur that require little or no investment by CBL. While we have certain properties where a more significant investment is warranted, to create higher long-term value, we are closely watching the total spend through this process. We expect total annual redevelopment spend to remain in the $75 to $125 million range for the next several years.

We'll continue to secure construction financing for the larger projects such as Brookfield Square. Following our dividend reduction last year, at the midpoint of our guidance range, we'll generate approximately $221 million of cash flow after the common dividend providing sufficient liquidity to fund these projects on a leverage-mutual basis. We are confident that the strategies we are executing on to redevelop our properties and diversify our tenancy in 2019 will position our portfolio for stabilization in 2020 and ultimately, a return to growth. I will now turn the call over to Katie to discuss our operating results and investment activity.

Katie Reinsmidt -- Chief Investment Officer

Thank you, Stephen. We made solid headway in 2018 toward recouping occupancy loss from bankruptcies and store closings in recent years. During the quarter, we executed over 1.3 million square feet of leases, bringing 2018 leasing activity to 4.2 million square feet. Same-center mall occupancy for the fourth quarter was 92.1%, representing a 130-basis point increase sequentially and a 10-basis point decline from the prior-year quarter. Portfolio occupancy of 93.1% represents an increase of 110 basis points sequentially and a 10-basis point decline compared to last year. Bankruptcy-related store closures impacted fourth quarter mall occupancy by approximately 70 basis points or 128,000 square feet. Occupancy for the first quarter will be impacted by a few recent bankruptcy filings. Gymboree announced the liquidation of their namesake brand and Crazy 8 stores. We have approximately 45 locations with 106,000 square feet closing.

We also have 13 Charlotte Russe stores that will close as part of their filing earlier this month, representing 82,000 square feet. Earlier this week, Things Remembered filed. We anticipate closing most of their 32 locations in our portfolio, comprising approximately 39,000 square feet. On a comparable same-space basis for the fourth quarter, we signed over 600,000 square feet of new and renewal mall shop leases at an average gross rent decline of 9.1%. Spreads on new leases for stabilized malls increased 2.6%. And renewal leases were signed at an average of 11.3% lower than the expiring rent. As we've seen throughout the year, certain retailers with precipitant sales declines have pressured renewal spreads. We had 17 Athena deals and two deals with Express this quarter that contributed 550 basis points to the overall decline on renewal leases. We anticipate negative spreads in the near-term but are optimistic that the positive sales trends in 2018 will lead to improved lease negotiations this year.

Same-center sales for the year reached $377.00 per square foot compared with $375.00 per square foot in the prior year. Our portfolio generated healthy increases in October and November, offset by declines in December. Categories that performed well included electronics, fast casual restaurants, shoes, and health and wellness. Regionally, sales were strong throughout the year in our Texas properties. Our anchor redevelopment program is making significant progress. While we are experiencing the impact to our income in the near term, we will build back a more diversified, higher credit quality income stream, as we make progress in replacing closed anchor locations. Our properties are not only the favored shopping destination in their margin but are becoming the go-to place for entertainment, dining, service, lodging, and more. And we have a ton of activity occurring across the portfolio. I'll review the projects currently under construction.

But I encourage you to review the department store activity schedule that we included in our supplemental package. It details the current status of every Sears and Bon-Ton box in our portfolio, whether it is operating, closed, owned, or leased. We have an impressive amount of deals that are in LOI stages or active negotiation. So, you can expect to see announcements from us on those deals as they come to fruition. At Jefferson Mall in Louisville, Kentucky, we celebrated the grand opening of Round One Bowling and Amusement in a former Macy's in November. This new use was very popular over the holidays and is generating considerable traffic at the center. Aubrey's Restaurant and Panda Express opened here in Chattanooga at Northgate Mall in the former Sears Auto Center space this month. Bonefish Grill and Metro Diner will open in the former Sears Auto Center location at Volusia Mall in Daytona Beach in the spring.

Construction is progressing on the first phase of the redevelopment of the former Macy's at Parkdale Mall. Dick's Sporting Goods, Five Below, and Home Goods will open this summer. Construction is well under way on the Sears redevelopment at Brookfield Square in Milwaukee, Wisconsin which is one of the stores we purchased in 2017 through a sale-leaseback. The first phase of this project includes a new Marcus Theater BistroPlex Diamond movie experience and WhirlyBall Entertainment Center. Two restaurants have already opened in all lots on the Sears parcel. And construction has commenced on the new hotel and convention center. We are under construction on Dave & Buster's at Hanes Mall in Winston-Salem in former shop space near the Sears wing with a opening scheduled for this spring. In Greensboro, at Friendly Center, O2 Fitness is under construction, replacing a former freestanding restaurant. The new 27,000 square foot location will open next month.

Here in Chattanooga, we opened Cheesecake Factory in early December on a pad in the Sears parking lot. Since their opening, they've enjoyed a strong reception with continuous long waits which has resulted in increased traffic to the mall. Sears closed their store here in January. And we expect to start construction on the redevelopment of this building in the spring. This project will include Dave & Buster's, a boutique hotel, Dick's Sporting Goods, additional restaurants, and office space. The hotel will be developed in a joint venture structure with a well-regarded hotel developer. Similar to other development joint-ventures, we have contributed land as our portion of the equity which allows us to realize value from our assets and to share in future upside. I will now turn the call over to Farzana to discuss our financial results.

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Thank you, Katie. In January, we closed on our new [inaudible] $1.185 billion credit facility with a maturity date of July 2023. This financing achieved a number of important goals for us. With this closing, we've addressed all of our unsecured maturities until 2023. We have also simplified our covenants. Going forward, we have one set of covenants calculated in a consistent manner with the unsecured notes. We have also rightsized our facility, eliminating a large unused fee but still providing more than adequate capacity. At closing, we utilized our new line of credit to reduce our outstanding term loans by $195 million to a total of $500 million. As a result, at closing, we had $420 million outstanding on our lines of credit, leaving $265 million of remaining volume capacity. We anticipate utilizing disposition proceeds and excess cash flow to reduce this balance over time.

We have a release provision under the new facility to unencumber properties as we make amortization payments on the term loan as well as release provisions for disposition or long-term property level financing. Using the midpoint of guidance, we estimate $220 million in cash flow after common dividends for 2019. This is more than sufficient to fund our redevelopment and maintenance CapEx as well as a term loan amortization of $35 million per year. We will also continue to be active in the disposition market. And to the extent we complete transactions, this will serve to supplement our free cash flow. We have provided proforma covenants for the new credit facility in the supplemental as well as some metrics on the unencumbered pool that will support the covenants going forward. The conversion of the line of credit in term loans to a secured facility increased the secure debt ratio to 34.9%.

The unencumbered pool is supported by NOI from our healthy and stable associated centers and community centers as well as stable malls including a number with redevelopments under way or in planning. In January, we completed the sale of Cary Towne Center and also completed the transfer of Acadiana Mall. The $163.5 million of related debt has been extinguished which will be reflected in our debt balance in the fourth quarter. We also expect to report a gain on extinguishment of debt related to both transactions which we will exclude from adjusted FFO. We have four secured loans maturing in 2019, two loans secured by Honey Creek and Volusia Mall in July. We've been in discussion with the lender and anticipate being able to announce a favorable resolution soon. We have $4.6 million loans secured by a phase of our Atlanta Outlet Center that we anticipate refinancing. We expect to wrap up these financings early in the year and begin focusing on 2020 maturities.

We have one additional secured mortgage that comes due in December. This loan was previously restructured and extended and continues to perform. We will evaluate our options and make a decision on our action plan closer to maturity. Our total pro rata share of debt at year-end was $4.66 billion, a reduction of approximately $105 million from year-end 2017 and a $27 million sequential decline. At quarter-end, net debt to EBITDA was 7.3 times compared with 6.7 times at year-end 2017. The increase was primarily due to lower total property level NOI. However, this should improve during the year with a reduction in debt related to Cary and Acadiana as well as property level and term loan amortization. Fourth quarter adjusted FFO per share was $0.45, representing a decline of $0.11 per share compared with $0.56 per share for the fourth quarter 2017. For the full-year, adjusted FFO was $1.73 per share compared with $2.08 per share in 2017.

Major variances included $0.08 per share dilution from asset sales in non-core properties, $0.20 per share from lower NOI-related, primarily to retailer and anchor bankruptcies. Other variances included $0.02 per share higher G&A, primarily related to retirement expense and $0.02 lower gains on our partial sales. During the quarter, we recognized impairments on two properties, Honey Creek Mall and Eastland Mall. I want to spend a minute to walk through these circumstances since both are unique. Honey Creek is secured by a non-recourse loan that matures in July and is cross-collateralized and cross-defaulted with Volusia Mall. As I mentioned, we've been working with a vendor toward a favorable resolution ahead of maturity. However, as a result of the imminent loan maturity, the whole pad is shortened. Coupled with changes to the projected NOI, the property, due to multiple anchor closures, our analysis determined that an impairment was appropriate at this time.

Eastland Mall has been the hardest hit from anchor closures, losing four department stores. We are in early stages of exploring several redevelopment options that would create future value while also limiting our capital investments. However, the impact of the lost land and co-tenancy related to the anchor closures on projected cash flow necessitates an impairment at this time. For the fourth quarter, same-center NOI decreased 4.4%, a sequential improvement from the third quarter same-center NOI. With this pickup for full-year 2018, we recorded a 6% decline in same-center NOI. This decline was primarily driven by loss rent related to retailer bankruptcies and rent reductions for certain struggling retailers. Expenses improved year-over-year as we worked to effectively manage cost. As Stephen indicated, our expectation for 2019 include assumptions for lost rent from anchor and store closures as well as low rent from renewals with struggling retailers.

The liquidation of Gymboree stores will result in a loss of gross annual rent of $3.7 million from our roughly 45 stores. This week, Charlotte Russe filed for bankruptcy and announced 13 store closures in our portfolio comprising $3.3 million gross annual rent. After the closures, well have 29 stores remaining, totaling $5.5 million in gross annual rent which would be at risk if they end up liquidating. Things Remembered also filed. And we expect the majority of their stores will close. We have 32 locations with approximately $2 million in gross annual rent. Our leasing team is already working on finding replacements for these locations. And our specialty leasing team will work to generate temporary income until a permanent replacement is found. We also focused on expense management and have taken steps to decrease overhead expense with reductions to executive and offers of compensation taking effect in 2019.

We anticipate interest expense to be flat to slightly up in 2019, as the higher rate on the credit facility is offset by interest savings from mortgage financings, lower total debt in a reduced, unused facility fee. We are providing an initial FFO as adjusted per share guidance of full-year 2019 in the range of $1.41 to $1.46 per share which assumes a same-center NOI decline in the range of 6.25% to 7.75%. Consistent with our approach last year, our guidance includes a top-line reserve to take into consideration the impact of unbudgeted bankruptcies, store closures, rent reductions, and co-tenancy that may occur. After reviewing our watchlist and our best assumptions, we've set the reserve in the range of $5 to $15 million to capture any losses that are above and beyond our budget. I will now turn the call over to Stephen for concluding remarks.

Stephen Lebovitz -- Chief Executive Officer

Thank you, Farzana. As I said earlier, we have made tremendous progress on our strategic priorities and are well-positioned to succeed despite the challenges we face. Our new credit facility removes short-term financial pressure and allows us to focus on achieving longer-term goals. We are actively elevating our assets, generating new income strains, and seeking out partnerships that supplement our capital sources and broaden our asset base. We are watching our capital allocation to ensure we are investing the right amount in the right projects and making tough decisions when they are necessary. Our goal as we move through 2019 is to position the portfolio for stabilization in 2020 and return CBL to growth. And I'm confident that we have the strategies in place to achieve this goal. Thank you for your time today. We will now open the call to questions.

Questions and Answers:

Operator

Ladies and gentlemen, we will now begin the question and answer session. To ask a question, please press * then 1 on your touchtone phone. If you're using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press * then 2. At this time, we will pause momentarily to assemble our roster. And our first question comes from Todd Thomas with KeyBanc Capital Markets. Please go ahead.

Todd Thomas -- KeyBanc Capital Markets -- Analyst

Hi. Thanks. Good morning. Just a little bit of clarification around some of the different buckets in the same-store guidance. I was just curious, Farzana -- so, you mentioned that there's $5.5 million in gross annual rent from the Charlotte Russe stores that are not currently closing. How is that factored into the guidance? Will that hit the reserve? Or is that factored into one of the other buckets?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Hi, Todd. Some of it is embedded in the numbers. But some of it will come off from the reserves. So, approximately $3 million will be in the $5 to $15 million reserve that we have established.

Todd Thomas -- KeyBanc Capital Markets -- Analyst

Okay. So, some of the bankruptcy impacted tenants if they closed stores that are in addition to what's already known. That would basically flow through the reserves, so the $5 to $15 million?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

That's correct.

Todd Thomas -- KeyBanc Capital Markets -- Analyst

Okay. And Farzana, so, you talked about some additional dispositions throughout 2019 to supplement cash flow. Are you currently marketing any assets for sale today? And are there any dispositions embedded in the 2019 guidance?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Well, no. The dispositions are not embedded. However, what we say is that we will supplement the free cash flow for investments and reduction in debt. So, we generally, every year, have about $30 to $35 million in proceeds from our parcel sales. So, that's one component. And then the other component is certain opportunistic asset sales that we will explore as we go forward. And we are working on some smaller ones. And we will let you know when we are able to accomplish those results.

Stephen Lebovitz -- Chief Executive Officer

Yeah. We don't like to comment on what we might be marketing because there's so many different ways you can market assets, whether it's through brokers or privately. And a lot of times, they're also exploratory, just to get a sense for the market. So, I think like Farzana said, we don't include it in guidance. And as something happens, and we announce it, then we would make the adjustment.

Todd Thomas -- KeyBanc Capital Markets -- Analyst

Okay. Thank you.

Operator

And our next question comes from Craig Schmidt with Bank of America. Please go ahead with your question.

Craig Schmidt -- Bank of America -- Analyst

Thank you. I wonder if you knew the number of assets in tier one out of the 18 that are unencumbered? And then how many of the 33 assets in tier two are unencumbered as well?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Well, the asset category has changed a little bit since we closed the loan. So, when we did close the loan, we had three assets that were tier one. And now, since we have changed the sales per square foot, there are four assets. And one of the assets has moved down to tier two. And one has moved down to tier three. So, it's sort of a mixed bag in terms of what's in tier one and tier two for the Wells Fargo lines of credit versus what's bond. But like I mentioned, for the bond's portfolio, the unencumbered piece that's left, we have a number of community centers and a number of associated centers. And a big portion are tier two properties. I don't have a count right now to give you. But the total count for the Wells Fargo line is about 17 properties in total.

Craig Schmidt -- Bank of America -- Analyst

Okay. Thank you. And then you currently have one of your seven redevelopment projects under development from tier three. I just wonder how active will you be in future redevelopments with tier three projects?

Stephen Lebovitz -- Chief Executive Officer

Yeah, Craig. For the most part, the redevelopments are focused on the higher sales per square foot centers. Although, in the case of Brookfield Square, it's misleading just because of the quality of the location and the market. And the project that we're redeveloping the Sears is outward facing theater, entertainment, restaurants, hotel, conference center. And so, we are creating value even on a freestanding stand-alone basis with that type of project. And that mall, over time, will continue to transition and have redevelopment opportunities. It's a great location. Tons of traffic on the roads and great visibility in a growing market. So, we evaluate each one individually. But that's the circumstances there.

Craig Schmidt -- Bank of America -- Analyst

Okay. Thank you.

Operator

And our next question comes from Rich Hill with Morgan Stanley. Please go ahead with your question.

Richard Hill -- Morgan Stanley -- Analyst

Hey. Good morning, guys. Maybe I can just start off with talking about other income. It looks like that increased, at least compared to our estimates, rather significantly compared to the prior quarter. Farzana, could you maybe walk through what was included in that?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Yeah. There's a reclassification going on. And I think you probably have seen that from other companies reporting that as well. So, there are certain income components that used to be included in the base rent. Some of them were in the tenant reimbursements. So, we have reclassified from tenant reimbursements to the other nine to the other category and also some lease income from other rent to other income which is some of the branding and sponsorship-type income.

Richard Hill -- Morgan Stanley -- Analyst

Got it. I'll probably follow-up offline just to get a little bit more detail and make sure it makes sense. I did wanna talk about your -- as just a quick, separate question -- your NOI on unencumbered assets. Just to make sure we're thinking about it correctly, I see around $168.5 million unencumbered NOI. Is that right?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Yeah. The total unencumbered NOI is approximately $365 million. So, it's now divided. It's split in half. Half of it went to the new credit facility. And half of it is still in the unencumbered pool.

Richard Hill -- Morgan Stanley -- Analyst

Got it. And so, that unencumbered NOI -- I know you gave negative-7% same-store NOI growth overall. Do you have any thoughts on how that unencumbered same-store NOI is trending compared to the overall guidance?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

No. I don't have that information, Richard.

Richard Hill -- Morgan Stanley -- Analyst

Okay. Great. That's it, guys. I'll probably follow-up offline. Thanks very much.

Operator

And our next question comes from Caitlin Burrows with Goldman Sachs. Please go ahead.

Caitlin Burrows -- Goldman Sachs -- Analyst

Hi. Good morning. Maybe just in terms of the same-store NOI in 2018 that came in right at the midpoint of your guidance. I was just wondering for 2019 and how you think about the reserve which is slightly smaller, would you say this reflects a smaller watchlist? Or how would you think about how you arrived at that reserve amount?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Yeah. Most of the bankruptcy that we know about now is all baked into our top-line numbers. So, what we have left is a smaller watchlist. Obviously, the reserve has been lowered because of that. So, this is all unknown from now on, whatever that comes up. So, we've provided for the $5 to $15 million bankruptcy reserve for that.

Caitlin Burrows -- Goldman Sachs -- Analyst

Okay. And then also, I was wondering if you could just remind us in terms of same-store NOI, does that include the impact of your anchor redevelopments? And if it does, do you know how much of a positive benefit that had in 2018 and what to expect for 2019?

Katie Reinsmidt -- Chief Investment Officer

Caitlin, we actually include some benefit if there's a redevelopment. But we also deduct the lost anchors. So, you can see on our same-store NOI reconciliation that we provided to get to the midpoint, we have that $1.8 million detraction from the anchor closures that's occurring. So, there is some benefit. But it's all recycled in together. Hopefully, we're doing accretive redevelopments that benefit NOI over the long-term. So, ultimately, it should improve the growth rate. But there's not a material uplift in 2019 relative to what we're seeing on the anchor closure side.

Caitlin Burrows -- Goldman Sachs -- Analyst

Got it. Just because there's a little offset from the improvement that you are getting.

Katie Reinsmidt -- Chief Investment Officer

Yeah. Exactly.

Caitlin Burrows -- Goldman Sachs -- Analyst

Okay. Thanks.

Operator

And our next question comes from Christine McElroy with Citi. Please go ahead.

Christine McElroy -- Citi -- Analyst

Hey, guys. Good morning. Understanding from Todd's question that you're not giving a disposition estimate. But just as we think about the $220 million of free cash flow expectation, can you give us the CapEx breakout for 2019 in terms of what you expect to spend this year on development and redevelopment and then the leasing CapEx bucket and the R&M CapEx bucket? And then what's left over for the line of credit paydown?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Yeah. We've noted that we have approximately $220 million in free cash flow after dividend payments. And we are expecting similar CapEx as we had in 2018, around $70-$75 million. And if you also add in some odd parcels sales that we have typically done every year, our cash flow should more than cover the amortization, not only the property level amortization but also the term loan amortization and also have sufficient funds between $75 to $125 million, as we noted, to spend on developments. So, it should pretty much balance out.

Christine McElroy -- Citi -- Analyst

Okay. And then in terms of line of credit paydown from where the balance is today, anything left over? Is there anything left over to go to that? Or is that any dispositions that you do would go to line of credit paydown?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Yeah. Well, generally speaking, the disposition proceeds have reduced our lines of credit over the years. And even last year, we had a considerable decline in our total debt balance, about $100 million. And largely, it came from disposition proceeds. So, that will continue as we have dispositions that will bring our lines of credit down. And also, the term loan will keep coming down because we are making amortization payments.

Katie Reinsmidt -- Chief Investment Officer

And Christine, I'd also mention the $75 to $125 million that Farzana talked about, we do get construction lands on some of our major projects like Brookfield. So, we would be using construction sources. It's a debt for debt swap. But that goes into the calculation as well.

Christine McElroy -- Citi -- Analyst

Okay. Gotcha. And then just as you think about the dividend level and maintaining, within the rules, your payout, maybe you could just walk us through a taxable income calculation now that you've got your budgeting done in terms of you've got the NOI decline. It sounds like interest expense is flat to up. But then to the extent that you expect to generate or use NOLs to offset the taxable income.

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

We just don't generally walk you through a taxable income calculation because it is a complex one. And I don't think it would be appropriate for us to do that. But I will tell you that as we looked ahead in 2019 and adjusted our dividends, it is to pretty much follow the taxable income that we expect to have in 2019. It will have some losses like for Acadiana Mall that will be part of it and Cary Towne Center. So, that's really where it will be. This is where we are projecting. But we watch it every quarter. And we view it. And we will make adjustments if we feel that that's appropriate. But at this time, our dividend is set for the next quarter or this quarter at seven and a half cents.

Christine McElroy -- Citi -- Analyst

Thank you.

Operator

And our next question comes from Tayo Okusanya with Jefferies. Please go ahead.

Tayo Okusanya -- Jefferies -- Analyst

Hi. Yes. Good morning. First of all, just congrats on all the progress with the debt refinancing and as well as a retenanting space. That's good information and good progress there. In regards to your loss provision of rent, the $5 million to $15 million, just from the initial comment about the three bankruptcies so far this year, that eats up about half of it at this point. If you end up in a situation where you do have a liquidation of one or more of the three tenants and then you continue to have store closures from some of your weaker tenants and your top-20 like Athena -- or in H&M, they're talking about clothing stores. Forever 21 is doing some rent modifications. How comfortable are you with that $5 to $15 range? And is there any risk it could get bigger?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Hi, Tayo. We have baked in all the bankruptcies that I just mentioned in my prepared remarks. So, the $5 to $15 is pretty much open right now for us to use if we have not budgeted them and we have some new information that comes up. But so far, all of the bankruptcies that I mentioned, they are already baked into our numbers, top-line --

[Crosstalk]

Tayo Okusanya -- Jefferies -- Analyst

So, the $5 to $15 is an additional provision?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

That's correct.

Katie Reinsmidt -- Chief Investment Officer

The only one that's outstanding is the Charlotte Russe where we mentioned that we had that $5 million annual gross rent exposure. But obviously, it would be prorated for -- if they happen to liquidate, it would be prorated for whenever their liquidation would occur. And we do also budget tenant by tenant or face by face. So, some of the stores are already budgeted to have rent declines or closures within our base budget. So, it wouldn't be that full $5 million impact coming out of the reserve.

Tayo Okusanya -- Jefferies -- Analyst

Okay. But if you do have a liquidation of any of those bankruptcies, that's not in your numbers. You just have what the stores you expect to close right now -- a liquidation would eat into the loss reserves, correct?

Katie Reinsmidt -- Chief Investment Officer

Well, the main thing is -- Gymboree was pretty much all the store closed anyway except for three or four Janie and Jack locations that we had. And Things Remembered, we expect them to close almost all if not all of their locations. So, that was already factored in.

Tayo Okusanya -- Jefferies -- Analyst

Into the numbers. Okay. That is helpful. And then just in regards to -- I know this is a very popular question. But within your market, can you just talk a little bit about, again, retailers who historically have not really had stores in your markets who you're starting to attract with some of your redevelopment projects?

Stephen Lebovitz -- Chief Executive Officer

Yeah. No. Thanks, Tayo. And thanks for your congrats on the loan recasts and the redevelopments. So, like I said in my remarks, we've got a lot of different non-apparel uses that we're adding. And it's really a combination coming from all different types of areas. And we're working with a number of alternative uses, mix-use. Like I said, the hotels and multi-family. But also, within retail, there's a lot of transition. There's new names that are e-tailers that we're in active discussions with and that we're meeting with. And hopefully, we'll be able to announce those in the not-so-distant future. And then the entertainment users that we're adding are new to the market. Dave & Buster's will be new to Winston-Salem or Chattanooga when they open. So, really, almost everyone we're working with is new to the market. And that's our goal is to use the closed department stores to transition these properties into different types of open air and more entertainment and food and mixed-use based projects.

Tayo Okusanya -- Jefferies -- Analyst

Gotcha. Okay. Gotcha. Helpful. Thank you.

Operator

And our next question comes from Linda Tsai with Barclays. Please go ahead.

Linda Tsai -- Barclays -- Analyst

Hi. When you discuss the multiple anchor closures that resulted in impairments to Honey Creek and Eastland, are there other malls in your portfolio that could see a similar situation in '19?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Hi, Linda. The impairment is a quarter by quarter process. We don't know at this point that we will have any other properties that will meet that criteria. But these two properties that I mentioned were significantly impacted because they had multiple anchors that left the center. So, at this moment, it's these two other ones that we have taken impairment on.

Linda Tsai -- Barclays -- Analyst

Okay. Thanks. And then on page five, in terms of the reconciliations to the same-store NOI, there's a couple of categories where you lump in two items. Can you give us a breakdown of the contribution -- so, for example, lease modifications and co-tenancy? That has a negative-1.4% impact. What percentage of that is lease modifications versus co-tenancy?

Katie Reinsmidt -- Chief Investment Officer

Yeah. We're not gonna be able to break it down any further than that, Linda. But that's our best estimate from each one of those larger categories. Obviously, it's all a little bit frangible. But we bucketed those together because they made sense.

Stephen Lebovitz -- Chief Executive Officer

Yeah. Linda, also, just back to your first question, we do have clarity now on Sears which is good. So, we know department stores that are closing. We know which are staying open, at least in the near-term. So, I think that gives us some comfort when we're looking -- and we've also, like I said, had a lot of success in backfilling these different department stores. And we have several that are opening. There are a couple that have opened. A lot they're opening this year. And so, that'll all counter any pressure on the properties from an impairment point of view.

Linda Tsai -- Barclays -- Analyst

Thanks for that. And then just finally, looking at page 37 to 38, in terms of the redevelopment plans for Sears and Bon-Tons, it seems like you guys are gonna be really busy. Are there any plans to do more hiring to help support these projects?

Stephen Lebovitz -- Chief Executive Officer

Well, the short answer is no. But we had, over the years, a pretty active new development program. And so, we've redeployed that expertise and that team to the redevelopments. And also, within leasing, we've set up redevelopment specialists. And it's working well. And yes, there's a lot out there. And everyone's really busy. But we feel like it's manageable. And as Farzana said, we're very cognizant of our G&A and managing expenses. And we've taken steps to reduce it for this year which we feel like is what we need to do because, like I said, our goal is really to get back on track from stability in our NOI and FFO and return the company to growth.

Linda Tsai -- Barclays -- Analyst

Thanks.

Operator

And our next question comes from Michael Mueller with JPMorgan. Please go ahead.

Michael Mueller -- JPMorgan -- Analyst

Yeah. Hi. On the, I think it was about $9 million of rent tied to the three bankruptcies that you mentioned, was that $9 million amount -- was that calendar-year amount? Was that an annualized amount? And what's currently in the run rate as you start 2019 that hasn't gone away?

Katie Reinsmidt -- Chief Investment Officer

Yeah. It was an annual number. It's gross annual rent. So, it's not prorated for the impact this year. We'll have to see when the store's closed for what that final impact will be. But we have included those numbers in our base guidance outside of --

[Crosstalk]

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

They're more conservative than not. That's what we have done.

Michael Mueller -- JPMorgan -- Analyst

Got it. Okay. Thank you.

Operator

And our next question is a follow-up from Christine McElroy with Citi. Please go ahead.

Christine McElroy -- Citi -- Analyst

Hey. Thank you. Just a couple quick follow-up. Just on Honey Creek and Volusia, I think, Farzana, that you said that you're coming to a resolution with the lender. And I realize you wrote down Honey Creek. Can you just give us a little bit more color on -- will that involve a reduction in the coupon and extension of those loans? Or maybe just some more color on that.

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

I'd like to finish our negotiations before I give you any information. So, it is under way. We hope to conclude it in the next 60 to 90 days. And we'll obviously let you know.

Christine McElroy -- Citi -- Analyst

Okay. Thanks. And then can you say what the debt yields were on Acadiana and Cary Towne Center?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Not really because we haven't been managing Acadiana for a number of months, almost over a year. So, I don't know what the NOI is today or when it went back to the -- there was a note purchase on it. The lender sold a note. And the note purchaser, we ended up giving our deed in lieu of foreclosure to the noteholder. So, we're not aware of generally, what the NOI was. So, I'm not so sure what they bought it for as well. But our debt, of course, was pretty high. So, I wanna say that debt yield was very low.

Christine McElroy -- Citi -- Analyst

Okay. And then just lastly, in terms of the 2019 commencement spreads that are in there, the negative-11.6%, would you expect -- based on the leasing that you continue to do for 2019 commencement, would you expect that to hold as we go through the year and you fill out that leasing?

Stephen Lebovitz -- Chief Executive Officer

Yeah. We think it's gonna get better. The sales have stabilized. And we had an increase. A lot of the leasing that we did involved high accuracy costs, renewals. And so, that was impacting the negative-11%. And we feel like the environment has improved. I think it's probably too optimistic to say it'll go positive. But we definitely think there'll be progress.

Christine McElroy -- Citi -- Analyst

Okay. Thank you, guys.

Operator

And the next question is a follow-up from Caitlin Burrows with Goldman Sachs. Please go ahead.

Caitlin Burrows -- Goldman Sachs -- Analyst

Hi, again. I guess I was just wondering since somebody else asked about it, and I was wondering -- rather than have to have multiple conversations on the idea of the tenant reimbursement income amounts and other income, could you give a little more detail on what that shift is? And when you net it together, is it both included in same-store? So, when you consider same-store, there's not really an impact?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Yeah. From a same-store basis, there will not be an impact. It's still in the revenue line item if you can think of it that way. It's in the top-line. So, apples to apples. Same-center NOI and the aggregate is comparable. Only the shift in the category, it's shifted from tenant reimbursements and minimum rent to other.

Caitlin Burrows -- Goldman Sachs -- Analyst

And any straightforward details or reasoning on why that is? Or it's just the way it is now?

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Oh, this is a new accounting rule change, standards change. And that's the reason for the reclassification.

Katie Reinsmidt -- Chief Investment Officer

Caitlin, it's revenue that's related -- non-lease revenue. So, it's for locations that are owned by the --

[Crosstalk]

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

And they pay a scan. You have to pull out the tenant reimbursement and move them into other. And then for branding income that's advertising and things like that, that's not related to leases. That comes out of other rents and moves into other income. It's --

[Crosstalk]

Caitlin Burrows -- Goldman Sachs -- Analyst

Got it. Okay. Yup.

Operator

And our next question comes from Haendel St. Juste with Mizuho. Please go ahead.

Haendel St. Juste -- Mizuho -- Analyst

Hey there. Good morning. A couple quick ones for me. Stephen, I was hoping you could elaborate on some comment you made earlier of expected stabilizations in 2020. Did that statement reflect an expectation from improved store closures, leasing spreads, saints or NOI? Maybe some color on that. And if so, what gives you the confidence to make that statement?

Stephen Lebovitz -- Chief Executive Officer

Sure. I'd say it's a couple of things. First of all, it is early in the year. So, I don't wanna be overly optimistic. But we do go through a process of budgeting out and just looking at where we've been from co-tenancy impact that'll burn off, backfilling of department stores, leasing progress that we'll continue to make, and then just the general discussions we'll have with retailers. We do feel like we're gonna be in a better position in 2020. And there's a lot of wild cards and variables that can come into play between now and then. And obviously, we won't be doing 2020 guidance until a year from now. But we're happy to talk about it. And it is really the combination that drives that sense of optimism.

Haendel St. Juste -- Mizuho -- Analyst

Got it. Got it. Okay. Thanks for that. And then I'm curious how your higher cost of capital might be impacting underwriting hurdles for your redevelopment projects. I'm wondering first, do you have higher return hurdles these days? And has that caused you to postpone or delay any projects you were considering starting?

Stephen Lebovitz -- Chief Executive Officer

Yeah. We've definitely looked hard at our redevelopment projects. Like I've said, we have a dozen where we're spending little or no money. So, we've looked to be creative as to strategies that we can backfill without using capital. And we're limiting the investment to ones where we see it's accretive to the asset of the value. And we've gone back and challenged our redevelopment team to reduce costs where possible. There is pressure on construction costs that has been a challenge. And the rent levels -- we wanna make sure that we're setting up the users for success. So, that's important to be realistic in our performance. But it's something that is very top of the mind for us as we look at just how precious every dollar is.

Haendel St. Juste -- Mizuho -- Analyst

Thank you.

Operator

And this concludes our question and answer session. I would like to turn the conference back over to Stephen Lebovitz for any closing remarks.

Stephen Lebovitz -- Chief Executive Officer

Thank you, everyone, for your participation. Today and we look forward to talking to you in the future or seeing you shortly. Thanks.

Operator

The conference is now concluded. Thank you for attending today's presentation. You may now disconnect. Duration: 53 minutes

Call participants:

Katie Reinsmidt -- Chief Investment Officer

Stephen Lebovitz -- Chief Executive Officer

Farzana Khaleel -- Executive Vice President and Chief Financial Officer

Todd Thomas -- KeyBanc Capital Markets -- Analyst

Craig Schmidt -- Bank of America -- Analyst

Richard Hill -- Morgan Stanley -- Analyst

Caitlin Burrows -- Goldman Sachs -- Analyst

Christine McElroy -- Citi -- Analyst

Tayo Okusanya -- Jefferies -- Analyst

Linda Tsai -- Barclays -- Analyst

Michael Mueller -- JPMorgan -- Analyst

Haendel St. Juste -- Mizuho -- Analyst

More CBL analysis

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

10 stocks we like better than CBL and Associates PropertiesWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and CBL and Associates Properties wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of January 31, 2019

Sunday, February 10, 2019

Pulse Biosciences, Inc. (PLSE) Q4 2018 Earnings Conference Call Transcript

Logo of jester cap with thought bubble.

Image source The Motley Fool.

Pulse Biosciences, Inc.  (NASDAQ:PLSE)Q4 2018 Earnings Conference CallFeb. 07, 2019, 4:30 p.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Good day, ladies and gentlemen, and welcome to the Pulse Biosciences Investor Update Conference Call. At this time, all participants are in a listen-only. Later, we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this conference call is being recorded.

I will now like to turn the conference over to Brian Dow, Pulse Biosciences' Senior Vice President and Chief Financial Officer. Sir, you may begin.

Brian Dow -- Senior Vice President and Chief Financial Officer

Thank you. And good afternoon, everyone. Welcome to Pulse Biosciences fourth quarter 2018 investor and analyst update call.

On the call with me today are Darrin Uecker, our President and Chief Executive Officer; and Ed Ebbers, our Executive Vice President and General Manager of Dermatology.

Before we begin, I would like to remind you that on today's call, we will be making forward-looking statements. These include statements regarding our plans, intentions and expectations relating to our commercial, operational, scientific, clinical and financial projections, financing plans, products, including the uses and applications of such products and other future events. You should not place undue reliance on such forward-looking statements as they are subject to a number of assumptions, risks and uncertainties, and may differ materially from actual results. These risks and uncertainties are more fully described in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K and mostly recently filed Quarterly Report on Form 10-Q. Investors are encouraged to reference these risks, uncertainties and other disclosures in those reports. Pulse Biosciences undertakes no obligation to update forward-looking statements as a result of new information or future events.

In addition, today's call is being recorded and will be available for audio replay on the Investors section of our website at www.pulsebiosciences.com shortly after the conclusion of the live call. Investors electing to use the audio replay are cautioned that forward-looking statements made on today's call may differ or change materially after the completion of the live call.

I would now like to turn the call over to our President and Chief Executive Officer, Darrin Uecker.

Darrin R. Uecker -- President and Chief Executive Officer

Thanks, Brian. Good afternoon, everyone and thank you for taking time to join us on today's call.

2018 was a very productive and important year in our mission to become a viable company at Pulse Biosciences. Before reviewing our progress in 2018 and how this is driving our milestones in 2019, the most important thing we want our shareholders and partners to understand today is that we have a clear vision for the commercialization of our CellFX System in aesthetic dermatology in 2019 and we believe this provides us a clear path to viability. Our mission -- our vision for our CellFX system in aesthetic dermatology is clear. Our CellFX system is a platform and we will deliver a growing array of valuable applications through the CellFX platform that patients will desire and aesthetic dermatology clinics will be excited to deliver for their patients. Our initial commercial applications will be in seborrheic keratosis, a common raised benign pigmented lesion on the skin and sebaceous hyperplasia, a small raised lesion caused by overactive sebaceous glands, typically on the face. These are both significant opportunities and where we have generated compelling clinical data. We have a growing pipeline of potential future applications, including warts, acne and basal cell carcinoma that take advantage of the mechanism of our NPS technology built on the success of the early clinical results and are in different stages of clinical development.

We believe the unique mechanism of our CellFX system provides the potential for many high-value applications in this field and we will continue to develop applications at a rapid pace through our clinical development programs. We are building a world-class team of experienced executives with successful track records in the field of aesthetic dermatology, who understand the business and have close relationships with the key opinion leaders in the field.

We will partner with clinics to build a franchise around the CellFX platform, providing the necessary training and tools to deliver safe and effective application outcomes that fit in the clinical workflow. We will leverage the growing digitization of healthcare by networking our CellFX systems, enabling a utilization-based business model and value-added services through the network to our clinic partners. The utilization-based business model aligns the incentives with the patient, the clinic and Pulse Biosciences and will be enabled by the connectivity of our CellFX system.

We will also continue to strengthen our competitive barriers around our CellFX system, the applications it delivers and the services we provide through the continued development of our intellectual property portfolio which now stands at 89 issued patents worldwide and 81 pending. We have a number of patents and patents pending directly related to skin treatments and the use of NPS and we continue to file the patent applications to further solidify our position in this field.

Finally (inaudible) our clear focus for 2019 is to commercialize in aesthetic dermatology and drive toward viability and the majority of our communication to shareholders will center around this focus. We remain steadfast in our belief that our NPS technology and our CellFX system has the potential to have broad applicability across many disciplines in medicine.

Our proprietary CellFX system is a highly differentiated and proprietary platform that uses ultra-fast electrical energy pulses with pulse durations from billionth up to a millionth of a second. This unique non-toxic and non-thermal mechanism is a biophysical mechanism brought about by the speed and amplitude of these energy pulses interacting with the internal structure of cells. And we will continue to explore how this unique mechanism can be applied to large unmet needs in medicine.

With that as a backdrop, I will now cover some of the more recent clinical progress in more detail before handing the call over to Ed to discuss our commercialization strategy in aesthetic dermatology.

We started 2018 with the release of our first clinical data in a dermatologic indication, the treatment of 58 patients with seborrheic keratosis or SKs, showing an 82% efficacy rate with a single treatment. This exciting data set not only identified an initial commercial application but validated a key mechanism of NPS, the ability to eliminate cellular lesions in the epidermis for the skin while sparing acellular structures, specifically, the dermis. Based on the positive SK data and our early histology studies on the use of our technology in different skin regions such as on the face, we identified another important capability of our NPS technology and that is the ability to target cellular structures in the deeper dermis while leaving the dermis unaffected.

With this understanding, our key opinion leaders immediately recommended a number of applications that they believed would be enabled by his capability and that are difficult to treat with conventional thermal modalities because of the damage those modalities do to the dermis. The initial application, which represents a clear and significant unmet patient need and what validate this capability was the targeting of sebaceous glands for the treatment of sebaceous hyperplasia or SH. SH lesions are yellowish, small papules, typically on the face and ranging from 2 millimeters to 4 millimeters in diameter and are 1 millimeter to 2 millimeters below the epidermis.

The treatment objective for sebaceous hyperplasia is to reduce or eliminate the enlarged sebaceous gland without damaging the surrounding dermis. We started our SH study with the goal of treating 60 patients in late June of 2018. By early September, we had treated 71 patients with a total of 222 SH lesions with the increase in enrollment being due to strong physician and patient interest. We recently reported, and included in today's press release, our top line results for this study. In this study, investigators evaluated SH lesion clearance at the final follow-up as either clear, mostly clear, partially clear or not clear as a standard measurement tool for these types of lesions and consistent with what we used for the SK study.

The results for lesion clearance, the primary efficacy endpoint, were extremely positive. 90% of the 222 treated lesions were rated as completely clear and 9.5% of lesions were rated mostly clear, with only one lesion rated as partially clear and zero lesions rated as not clear. Also of note, 92% of the lesions were rated clear or mostly clear after a single treatment with the remaining 8% being treated a second time and again, all the -- one lesion was rated clear or mostly clear following that second treatment. These efficacy results exceeded the investigators' expectations.

We also reported on patient satisfaction, where 78% of lesion outcomes were rated as satisfied or mostly satisfied by the patients, a very positive result for an initial study in a difficult to treat lesion, but also leaving an opportunity for improvement (inaudible) 100% efficacy rate. Based on the learnings from this study, we are confident we understand how to raise the patient satisfaction into the high 90%s range and believe it will be at these levels in the commercial setting.

We believe this SH application data provides the required clinical efficacy and safety data to pursue a specific FDA indication. The SH data set will be presented by Dr. Gilly Munavalli at the upcoming Annual Meeting of the American Academy of Dermatology on March 1st through the 5th in Washington DC and by Dr. Suzanne Kilmer at the upcoming Annual Meeting of the American Society of Lasers in Medicine and Surgery on March 27 through the 31st in Denver, Colorado. We look forward to the SH data set being presented from the podium at these prestigious meetings.

The results of the SH study not only give us confidence in the SH application as a clear commercial application for our CellFX system, but also opens new application doors based on this clear demonstration of being able to treat cellular structures in the deeper dermis. In fact, based on these results, our KOLs suggested we immediately begin a feasibility study in moderate to severe back acne on the knowledge that the sebaceous glands play an important role in acne.

In late 2018, we began working toward a feasibility study and today we announced the first patient treatment in our back acne feasibility study. The study will treat up to 20 patients with the objective of demonstrating that our CellFX procedure can target the sebaceous glands across a large area on a back acne patient and reduce the number of new acne eruptions when compared to untreated skin. This first step will provide important insights into the potential benefits of our CellFX system in treating this condition and we look forward to communicating our results as they are available.

Dr. Mark Nestor, Managing Partner of Skin and Cancer Associates and Dr. Brian Berman, Professor Emeritus of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine are the principle investigators on this study.

In Q3 of 2018, we treated our first patient in our feasibility study in warts. Similar to SKs, warts reside largely in the epidermis and the current treatment modalities have limited efficacy. Warts are consistently one of the top identified problems for patients seeking treatment from dermatologist. This feasibility study will enroll up to 20 patients and it's being led by Dr. Vic Ross at the prestigious Scripps Clinic in San Diego.

As we noted in the Q3 investor call, and reaffirm here, we expect to report out this data in early Q2 2019 after completing enrollment this quarter. The objective of the feasibility study is to identify which types of warts are best treated by or CellFX system. In anticipation of the positive results from the study, we are preparing for a multi-center indication study that we are planning to begin in late -- in quarter two of 2019.

During 2018, we also initiated and are currently executing a treat and resect study in basal cell carcinoma or BCC, the most prevalent form of skin cancer. We believe BCC is an exciting therapeutic opportunity and represents a bridge between our developments in dermatology and those in oncology. This is our first NPS human study in skin cancer and will allow us to look at both the ability of NPS to eliminate the BCC lesion and the immune response changes as a result of the NPS treatment.

This is not a therapeutic endpoint study, but this is an important first step that enables us to move quickly to demonstrate safety and NPS effect in a skin cancer and sets us up for a follow-on study aimed at the therapeutic endpoint. Thanks to our oncology and dermatology advisors, we were able to move rapidly into the study and we are already making plans for a follow-on study so that we can move quickly as the data comes in. We expect to have initial data within this quarter and look forward to reporting on it.

An important milestone for commercialization will be an FDA regulatory clearance for use of our CellFX system in dermatology. Based on our previous conversations with the FDA and knowledge gained from those interactions, we plan to pursue a 510 (k) clearance for specific indications in aesthetic dermatology, including our SK and SH data. We previously communicated a submission that occurred during this quarter, quarter one 2019, and we are on track for this to take place. We believe the 510 (k) process is the appropriate path to this indication and look forward to the submission and to working with FDA to ensure we provide all the required data. Based on our plans for submission and 510 (k) timelines, we are planning for a clearance in the third quarter of 2019.

We believe that 2018 (ph) will prove to be a seminal year in establishing the CellFX system as a unique treatment energy modality with a wide variety of potential clinical applications. And 2019 will be the year we launch this exciting technology commercially into aesthetic dermatology.

With that, I would like to turn the call over to Ed to discuss the steps we're taking to prepare for commercial launch in this exciting market.

Ed Ebbers -- Executive Vice President and General Manager, Dermatology

Thank you, Darrin.

I am very pleased to report on our progress in planning a world-class launch for our CellFX system in this aesthetic procedures market. This large and growing market is composed of a concentrated group of dermatologists, plastic surgeons and other skin care specialists with a known history of purchasing and using energy-based devices to perform various procedures on the skin for both aesthetic and clinical applications.

The economic trends and demographics of an aging population and the associated conditions of aging skin provide a significant opportunity for launching a new technology in this category. The foundation of the commercialization strategy for our CellFX system to this growing market is composed of three major components. First, build a sales and marketing team with a proven track record in launching devices and increasing device utilization over time in true collaboration with the key opinion leader specialty physicians that have a history of successful clinical and commercial excellence in adopting new technologies in this aesthetic procedure market.

Second, create a first wave of key opinion leader acceptance and advocacy of our CellFX system that validates high patient satisfaction and proven commercial success. This successful CellFX adoption of the first wave of key opinion leaders, or KOLs, leads to a rapid uptake for the next wave of early adopters with a highly efficient sales and marketing investment.

Third, continue generating high quality scientific evidence that proves a superior profile for both current and anticipated future clinical applications that increase the utilization revenue that Pulse earns with every use of its device.

First let's discuss building a world-class sales and marketing team. We recently announced the hiring of Robert Tyson as Vice President of North American Sales. Bob is one of the most experienced and successful sales executives in this market. He has an established track record of delivering results by building and managing high performing sales teams for category leaders like ZELTIQ, Ulthera, Miramar Labs and Thermage. These technologies are all examples of the successful utilization-based business models that closely resemble our commercial model for our CellFX system. And we will build our team around this proven model.

For the introduction of our CellFX platform, which is initially focused on the domestic market, our sales team is being built to scale over time to reach a target group about 4,000 specialty physicians in the United States. Among this target group of 4,000 physicians, there is a relatively small core of key opinion leaders. Our early launch efforts are focused achieving early clinical and commercial success with this influential core of KOLs located in major markets. When we are successful in earning KOL acceptance and advocacy for our CellFX system and procedures, their influence on the next wave of early adopters is a powerful predictor of success. This core of KOL support, along with our continued outstanding clinical data will lead to podium presentations at major meetings, media exposure in major markets and results in a stream of publications of our outstanding scientific evidence for clinical applications.

Our success with this small group of KOL physicians, along with continued favorable clinical data published on new applications set the stage for the first wave of early adopters that we expect to purchase our CellFX platform in the future.

In our next quarterly call, we will discuss the specific initiatives designed to gain the trust and advocacy of this influential group of respected key opinion leaders. This leads to the final element of our commercial launch foundation, the continued generation of high-quality scientific evidence that supports both current and future applications. This drives the routine utilization of our device and the revenues that this generates.

Our first two targets, seborrheic keratosis, SKs and sebaceous hyperplasia, SH are both examples of high-value, difficult to treat skin conditions for which our initial study show outstanding efficacy and visible proof of a non-thermal mechanism of action that targets cellular lesions or structures without damaging the non-cellular dermis. Our early market research with our target physicians has shown that patients with these two common lesions are already being seen by our target physicians over 300 times per month. So there's a ready pool of patients available for a CellFX procedure.

This is just the beginning of our potential market opportunity. Based on our success in clearing these first two common examples of visible skin lesions and relying on the advice of our Scientific Advisory Board, we are aggressively pursuing evidence of efficacy and utility in treating other skin lesions and conditions that have similar attributes for which our cell-specific mechanism of action has likely effect. We have already discussed warts, acne and basal cell carcinoma. Our application development pipeline continues to reveal promising targets that will add to the utilization potential of our future growing installed base.

To summarize, as we grow the sales team and continue to build on our successful relationships with KOLs, we will drive the acceptance of our CellFX system and its growing portfolio of applications to the large potential installed base of our targeted specialty physicians. And our ever-increasing utilization-based business model will drive value for our installed base of physicians and offer a unique technology to skin problems of patients that they see every day. I look forward to reporting on our commercial plans and progress in the quarters to come as we continue our ambitious launch effort for the CellFX technology and reach our goal of changing the way the skin specialists treat benign and non-benign lesions and help patients improve the quality of their skin.

That concludes my remarks on the commercial launch plans for our CellFX system and I'm turning the call over to Brian to discuss Pulse's financial highlights.

Brian Dow -- Senior Vice President and Chief Financial Officer

Great. Thanks, Ed. Before we reported today's call, we announced our financial results for the fourth quarter and year ended December 31st, 2018. Our financial results for the quarter and the full year reflect the progress achieved in our development and clinical programs, accompanied by the requisite support infrastructure of those endeavors and operations of a public company.

Cash and investments at December 31st, 2018 total totaled $59.6 million compared to $21 million at the end of the third quarter and $38.1 million at the end of 2017. The 2018 year-end balance reflects the proceeds from our recently completed rights offering. During December, we successfully completed a $45 million financing in which we received $44.8 million from the sale of 3.6 million shares of common stock at a price per share of approximately $12.57. We pursued the rights offering as a mechanism for this capital raise, as it provided an efficient stockholder friendly path on the company. Through this offering, all stockholders were afforded the right to participate and it avoided a number of the customary transaction expenses of a traditional financing. The success of this financing affords the resources necessary to accelerate our progress toward commercialization and enhancing the utility and value of our CellFX system.

During the fourth quarter of 2018, our ongoing development activities, advancement of our clinical studies, the introduction of the CellFX systems into those clinical studies and the continued growth of our business, drove our fourth quarter cash use of $6.4 million, bringing the total cash use for the year to $23.5 million, slightly below our previous guidance of $24 million for the year.

Turning now to operating results for the fourth quarter and for the year ended 2018. Net loss for the fourth quarter of 2018 totaled $9 million, reflecting a $300,000 or 3% increase compared to the net loss of $8.7 million for the fourth quarter of 2017. Net loss for the periods include non-cash stock-based compensation charges totaling $2.4 million and $4.5 million for 2018 and 2017 respectively. Year-to-date net loss for the 12-month period ended December 2018 totaled $37.5 million, reflecting an $11.9 million or 47% increase compared to the net loss of $25.6 million during the year ended 2017.

Stock-based compensation charges reflect a significant component of the expense incurred in both periods, contributing $12.3 million and $10.9 million to the results for 2018 and 2017 respectively. The year-over-year increase in net loss reflects the progress of expanding our CellFX development and clinical programs and building our Company over the intervening period. Headcount has increased to 54 at December 31st, 2018 from 33 a year earlier and currently stands at 62. To put this in perspective, at December 2016, headcount totaled 13.

Research and development expenses increased to $5.1 million for the fourth quarter of 2018, an increase of $2.2 million or 77% compared to $2.9 million for the fourth quarter of 2017. On a year-to-date basis, R&D expense increased to $17.3 million from $9.6 million during the prior year, an increase of $7.6 million or 79%. A significant portion of the increase reflects the increase in R&D personnel. R&D headcount increased to 41 as of December 31st, 2018, up from 24 at December 31st, 2017 and 9 at the beginning of 2017.

Also contributed to increased R&D expenses are increases in clinical trial expenses, reflecting increased activity surrounding our completed and ongoing studies, specifically our SK and SH studies for which data has been announced and our warts and BCC feasibility studies that remain under way. Protocol development for recently commenced and soon to commence studies, including the acne feasibility study announced earlier today, engineering and prototyping expenses reflecting the design, development and manufacture and deployment of CellFX systems to our clinical study sites and support expenses relating to the increase in the breadth of R&D activities.

R&D expenses will continue to increase going forward, reflecting ongoing engineering and development work, focused on refinements to our CellFX system in preparation for commercial introduction later this year, our ongoing and planned clinical studies and future preclinical research further expanding the utility and value of our NPS platform.

Turning now to general and administrative expenses. G&A expense decreased to $3.8 million for the fourth quarter of 2018, a decrease of $2 million or 34% compared to the $5.8 million reported for the fourth quarter of 2017. On a year-to-date basis, G&A expense increased to $20 million from $15.5 million in the prior year, an increase of $4.5 million or 29%. The quarter-over-quarter decrease is primarily attributable to a significant decrease in non-cash stock-based compensation. On a year-over-year basis, the increase (inaudible) can be attributed to increased expenses in compensation, professional services and consulting. Increased compensation expense reflects increased headcount as G&A (inaudible) increased to 13 (ph), increased legal expenses, reflecting the ongoing development of our intellectual property estate, our reincorporation in Delaware earlier this year, registration statements for past financings, SEC matters and ongoing public company support. Consulting and outside services predominantly increased, reflecting resources contributing to ongoing development of our intellectual property estate and strategic planning initiatives. As we build out our sales and marketing and manufacturing operations on the path to commercialization of our CellFX system, continue to maintain and expand the depth and breadth of our IP estate, and implement the requisite support infrastructure, we expect G&A expenses to increase during 2019.

That concludes my prepared remarks. I will now turn the call back to Darrin.

Darrin R. Uecker -- President and Chief Executive Officer

Thanks, Brian. In 2018, we made significant progress in demonstrating that our proprietary NPS technology can produce compelling clinical data in difficult to treat skin applications, in particular, in SK and SH lesions. And we are more confident than ever that there are many applications that will be well served by our CellFX system. In fact, there are several that we discussed on this call and are currently under development.

In 2019, our focus is on bringing our CellFX system to the aesthetic dermatology market. As I mentioned in the opening remarks, our vision for our CellFX system in aesthetic dermatology is clear, our CellFX system is a platform, and we will deliver a growing array of valuable applications or apps that patients will desire and aesthetic dermatology clinics will be excited to deliver for their patients. We will develop a network of our CellFX systems that will allow us to provide best-in-class training and service to our customers.

In 2019, we will be focused on the successful commercial launch of our CellFX system and to laying the foundation for future growth of the business. An important milestone will be an FDA regulatory clearance, and as I mentioned previously, we expect to submit a 510 (k) with FDA this quarter and based on review timing, we are targeting a Q3 clearance. Once we receive the regulatory clearance, we will proceed with our launch through key KOLs as described by Ed on this call. We plan to announce when the 510 (k) is submitted and we will provide updates as appropriate.

We also continue our development of applications in 2019. We anticipate our wart study and BCC study data to be available by the end of Q1 and we anticipate moving those programs forward in Q2. In warts, we are planning a follow-on study that would generate sufficient data to drive a commercial application, which if successful would likely be introduced in late 2019 or early 2020. We will provide further details as the follow-on study is initiated.

BCC will likely have a longer timeline given that it is a skin cancer. We will provide additional details on the schedule for this application as we get through this first important study.

We expect the back acne feasibility study to take into Q3 before we will have sufficient data. Again, as the data is available, we will communicate plans for future studies.

In addition to these, we expect to initiate studies in new applications, either as feasibility studies or indication studies that leverage the mechanism of action and unique capabilities of the CellFX system. As we have done in the past, we expect to communicate details of these studies as we begin treating patients.

To wrap up our prepared remarks, I would simply say, we are very excited as a company to be driving toward commercialization in such an exciting market in 2019. As we move through 2019 and approach our commercial launch, we will provide additional details on launch plans and metrics for our commercial business. In short, we are in the apps business and apps will drive utilization, which will be good for patients, physicians, clinics and the viability of Pulse Biosciences.

That concludes our prepared remarks. Operator, we would now like to open the call to questions.

Questions and Answers:

Operator

Thank you. (Operator Instructions)

Our first question comes from the line of Swayampakula Ramakanth with H.C. Wainwright. Your line is now open.

Swayampakula Ramakanth -- H.C. Wainwright & Co. -- Analyst

Thank you. Thank you for taking my questions.

Darrin R. Uecker -- President and Chief Executive Officer

(multiple speakers) good afternoon.

Swayampakula Ramakanth -- H.C. Wainwright & Co. -- Analyst

Good afternoon. The hyperplasia data certainly looks impressive. My question here is, what are the physicians offering at this point to this -- these sets of -- this set of patients and what competition does CellFX system face when it enters the market with these physicians who are offering -- what are they offering to the hyperplasia patients?

Ed Ebbers -- Executive Vice President and General Manager, Dermatology

Yes, this is Ed Ebbers answering your question. The sebaceous hyperplasia market currently has no reasonable choices for physicians to employ to patients who have these problems. By and large, the available tools cause more damage than the original problem, so patients are displeased with any potential cosmetic outcomes. So by and large, the physicians avoid the treatment of sebaceous hyperplasia. This is because most technologies are thermal and these thermal technologies have to reach deep sebaceous glands in order to achieve and affect and because they are thermal, they cause damage on the way down. Because of our unique ability to affect the cells of the sebaceous gland, we're able to safely reduce these glands without damaging the surrounding dermis. So this ability to target the gland without causing collateral damage provides a unique efficacy but also unique cosmetic outcomes once the lesions have been removed.

To our knowledge, there are no other available technologies studying sebaceous hyperplasia at this time. And to our knowledge, we have a unique effect that no one's been able to duplicate with other forms of energy technology or pharmaceutical intervention.

Swayampakula Ramakanth -- H.C. Wainwright & Co. -- Analyst

Thank you. Thank you, Ed for that answer. Regarding back acne, could you help us understand the dynamics of that market and how big of a market back acne is as such?

Darrin R. Uecker -- President and Chief Executive Officer

Hey RK, this is Darrin. Yeah, I think what we would say right now is kind of what we said in the prepared remarks, which is the acne was something that was very strongly recommended by our key opinion leaders, our Scientific Advisory Board as something that we should go after based on the results that they saw from our SH study, and again the link there is the sebaceous gland. What I would say right now is that this back acne study is a feasibility study, we treated our first patient today. So the effect -- the effect that we have and where that opportunity may guide us, I think we'll reserve for future discussion as that data starts to come in.

I think if you talk to dermatologists, they obviously -- acne is a big problem and where we fit in that problem, I think will be borne out from the data, in our early feasibility data perhaps. So I think until we get a little further down the road, we wouldn't talk too much about the specific opportunity, it's more that based on our observations of treating the sebaceous hyperplasia, we feel like this is something that we can definitely have an impact on.

Swayampakula Ramakanth -- H.C. Wainwright & Co. -- Analyst

Great. Thank you, both. Thanks for taking my questions.

Darrin R. Uecker -- President and Chief Executive Officer

Yeah, thanks (multiple speakers).

Ed Ebbers -- Executive Vice President and General Manager, Dermatology

Thank you, RK.

Darrin R. Uecker -- President and Chief Executive Officer

Yeah, thanks a lot for listening in and good questions, RK.

Operator

Thank you. (Operator Instructions) And our next question comes from the line of Dick Jan (ph) with Pulse Biosciences (ph). Your line is now open.

Dick Jan -- -- Analyst

Hello?

Darrin R. Uecker -- President and Chief Executive Officer

Hello.

Dick Jan -- -- Analyst

(inaudible)

Darrin R. Uecker -- President and Chief Executive Officer

Hello, Dick.

Ed Ebbers -- Executive Vice President and General Manager, Dermatology

Yes, hi.

Darrin R. Uecker -- President and Chief Executive Officer

Hi Dick, we can hear you.

Dick Jan -- -- Analyst

Okay, thank you. I would like to talk about CellFX, a little bit about your research into cancer, specifically your dog liver treatment that was announced a couple of years ago, but we haven't heard anything about it since. And I would like to know what the progress has been on the treatment of the dog liver, the canine program?

Darrin R. Uecker -- President and Chief Executive Officer

Okay, thanks. Thanks a lot for listening in, Dick and thank you for the question. So in 2018, we started a veterinary medicine study. It wasn't in the liver cancer, it was actually in stage 1, 2 canine oral melanoma. So this is a study that we started in the, I believe, in the second half of the year. So we entered into that study to continue to explore the use of NPS and our technology in an oral lesion and continue to build data on the safety profile of our technology in the treatment of that oral lesion. At the time that we started or announced that we were going to be in that study, we communicated our intent was to start a study that would provide additional data as sufficient data became available.

This study is ongoing, it's currently enrolling. I would say it's enrolling a bit slower than we had anticipated. But that being said, we expect to report on that data when we have sufficient data to report any definitive results. So at this time, we're not reporting on that. I expect we'll be able to report more definitive data in the upcoming calls, perhaps in the Q1 call.

Dick Jan -- -- Analyst

Okay. Well, in your recent option program, you (inaudible) sell half of the Company to existing shareholders, as I understand it, for $45 million. And effectively, that told us that the whole company was worth $90 million. And what I'd like to know is do you have any kind of internal information concerning the future of treatment of internal cancers that would make value of the company more than $90 million?

And if (multiple speakers).

Brian Dow -- Senior Vice President and Chief Financial Officer

Okay, Dick, this is Brian. I'm going to jump in here for just a second. It wasn't 50% of the company, we sold 3.6 million shares out of what at the time was roughly 17 million shares. So you're really looking more in the 15% to 20% value of the Company. And when we're looking now, we're looking at 20 million shares outstanding and with the current market conditions, we're looking at a market capitalization in the neighborhood of $300 million. So I'm not sure where the 50% and $90 million numbers are coming from. So that's...

Dick Jan -- -- Analyst

All right. But when the -- selling stock for -- my problem is that I wonder if the value of the company, is -- was increased by that $45 million because of (expletive).

Darrin R. Uecker -- President and Chief Executive Officer

Okay, operator, maybe we should prompt to to see if there are any other questions.

Operator

Yeah, thank you. (Operator Instructions) And we have our next question from the line of Andrew Savis (ph) a private investor. Your line is now open.

Andrew Savis -- -- Analyst

Hey guys, well done.

Darrin R. Uecker -- President and Chief Executive Officer

Hey, Andy, thank you. Good to hear from you.

Andrew Savis -- -- Analyst

Yeah, and the same here. (inaudible) I have a question on future revenue. As I see it and correct me if I'm wrong, or just -- hopefully I'm right, this should be three to four different ways to receive revenue once you're commercially approved, and your sales teams start going closing sales and expanding. One will be the sale or the lease of the CellFX system, two would be per application, am I correct so for? Then three would be continuous supplies and service. Would that all those four items be your source of income, am I right or wrong on that stuff?

Brian Dow -- Senior Vice President and Chief Financial Officer

Okay. Hey, Andy, it's Brian. Thanks for your question. The new revenue streams are going to be predominantly from two main sources. First is going to be from the initial placements of the CellFX systems. So in Ed's remarks, he discussed the target clinicians that we'll be going -- we'll be pursuing and placing systems with. Subsequent to that and more importantly to that will be the procedure revenue. We've designed the system and we're implementing a business plan that is oriented toward aligning Pulse Biosciences with the interest of the clinics so that for each use of the system, we're generating revenue off of those systems thereby every -- when we make investments into these additional applications, utility of the system is increased and the number of procedures that the system can be used for increase. So it's a per click revenue model.

Andrew Savis -- -- Analyst

Okay. Now, when you do a procedure, do you need to replace a -- I'm basing this on (inaudible) they either sell or lease their machines and they get the -- they make a lot of money from replacing whatever they need for the application, as a price and also service. Do you need to replace anything or add on to anything in that CellFX system that would generate revenue or it's just per application?

Brian Dow -- Senior Vice President and Chief Financial Officer

Thank you for giving us a chance to clarify along those lines. First, on the initial placements, just for clarity, we would be actually selling the systems, at this time, we're going to be -- it will be a purchase from the clinicians on the upfront side. Now on the back end, yes, there are consumables that will be used in the process, but we are actually using a different model wherein it is a -- the CellFX system will be networked and from that the clinician will download treatment cycles or cycle units to the system and utilize those cycle units in treating patients and it is those cycle units that will be the source of revenue for Pulse Biosciences, it will not be purely the consumable and selling the consumable.

Andrew Savis -- -- Analyst

That's fine. I like that. Thanks (ph) very much. The other thing, do you also have a service contract with the -- where you can actually make money on the machine if necessary?

Brian Dow -- Senior Vice President and Chief Financial Officer

There are opportunities for that. At this point, the key attributes that really are going to be the value drivers are going to be in the procedure revenues that will be driven by the system placements.

Andrew Savis -- -- Analyst

Okay. Do you have any idea what these systems will be selling for? Any range or you haven't decided yet?

Brian Dow -- Senior Vice President and Chief Financial Officer

Well, we have previously announced that we're expecting to place these systems in the neighborhood of $45,000 to $50,000 in the initial launch.

Andrew Savis -- -- Analyst

Thank you for that. And approximately how much for procedure -- each procedure is different in cost?

Brian Dow -- Senior Vice President and Chief Financial Officer

You know, we will be in a position where we'll be giving additional transparency and resolution to what we'll be doing on the commercialization standpoint, from a pricing and revenue standpoint, as we get closer to the introduction into the commercial market.

Andrew Savis -- -- Analyst

Okay. Then I have a little more personal question. I have a friend who has a few clinics, he is a plastic surgeon (inaudible) I hope to put him in touch with and when you're ready to launch.

Ed Ebbers -- Executive Vice President and General Manager, Dermatology

Okay. This is Ed, please feel free to drop me a email with his name and contact information, I will make sure he is on the contact list once we proceed in our commercial launch mode. Thank you.

Andrew Savis -- -- Analyst

Yeah, he's in Manhattan and I'll -- he just wanted me to find out approximate timing, I told him probably maybe, my guess was late summer, but that's my guess. Okay.

Darrin R. Uecker -- President and Chief Executive Officer

Thank you.

Brian Dow -- Senior Vice President and Chief Financial Officer

Great. Thanks, Andy.

Andrew Savis -- -- Analyst

You're welcome.

Operator

Thank you. Ladies and gentlemen, this concludes today's Q&A session. I would now like to turn the call back over to Darrin Uecker for any closing remarks.

Darrin R. Uecker -- President and Chief Executive Officer

Thank you, operator. Thank you for joining us on today's call, everyone. It's an exciting time for Pulse Biosciences as we drive to the commercial introduction of our CellFX system. We look forward to sharing our progress with you on our next call.

Operator

Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program and you may all disconnect. Everyone, have a wonderful day.

Duration: 46 minutes

Call participants:

Brian Dow -- Senior Vice President and Chief Financial Officer

Darrin R. Uecker -- President and Chief Executive Officer

Ed Ebbers -- Executive Vice President and General Manager, Dermatology

Swayampakula Ramakanth -- H.C. Wainwright & Co. -- Analyst

Dick Jan -- -- Analyst

Andrew Savis -- -- Analyst

More PLSE analysis

Transcript powered by AlphaStreet

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.